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Background. It is unknown whether rising incidence rates of nosocomial bloodstream infections (BSIs)
caused by antibiotic-resistant bacteria (ARB) replace antibiotic-susceptible bacteria (ASB), leaving the total BSI
rate unaffected.
Methods. We investigated temporal trends in annual incidence densities (events per 100 000 patient-days) of
nosocomial BSIs caused by methicillin-resistant Staphylococcus aureus (MRSA), ARB other than MRSA, and ASB
in 7 ARB-endemic and 7 ARB-nonendemic hospitals between 1998 and 2007.
Results. 33 130 nosocomial BSIs (14% caused by ARB) yielded 36 679 microorganisms. From 1998 to 2007,
the MRSA incidence density increased from 0.2 to 0.7 (annual increase, 22%) in ARB-nonendemic hospitals, and
from 3.1 to 11.7 (annual increase, 10%) in ARB-endemic hospitals (P = .2), increasing the incidence density diffe-
rence between ARB-endemic and ARB-nonendemic hospitals from 2.9 to 11.0. The non-MRSA ARB incidence
density increased from 2.8 to 4.1 (annual increase, 5%) in ARB-nonendemic hospitals, and from 1.5 to 17.4
(annual increase, 22%) in ARB-endemic hospitals (P < .001), changing the incidence density difference from −1.3
to 13.3. Trends in ASB incidence densities were similar in both groups (P = .7). With annual increases of 3.8%
and 5.4% of all nosocomial BSIs in ARB-nonendemic and ARB-endemic hospitals, respectively (P < .001), the
overall incidence density difference of 3.8 increased to 24.4.
Conclusions. Increased nosocomial BSI rates due to ARB occur in addition to infections caused by ASB, in-
creasing the total burden of disease. Hospitals with high ARB infection rates in 2005 had an excess burden of BSI
of 20.6 per 100 000 patient-days in a 10-year period, mainly caused by infections with ARB.
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Rates of nosocomial bloodstream infections (BSIs) caused by
antibiotic-resistant bacteria (ARB) are increasing worldwide
[1]. Yet, associated changes in total burden of disease and the
dynamic interaction between ARB and antibiotic-susceptible
bacteria (ASB) have not been accurately quantiﬁed [2]. For in-
stance, one could hypothesize that the frequent use of antibi-
otics in hospitalized patients creates an ecological niche for
ARB that replace ASB, without increasing the total burden of
disease. Alternatively, ARB and ASB may not compete, and,
thus, increasing infection rates caused by ARB incur an addi-
tive burden. Such information is critical for quantifying the
health-economic effects of antimicrobial resistance and dem-
onstrating the beneﬁts of infection control [3]. Most longitudi-
nal studies on the epidemiology of ARB addressed a single
pathogen, frequently with comparison to its antibiotic-suscep-
tible variant, but failed to include all other pathogens [2]. To
assess whether incidences remain stable or increase, one
should adjust for changes in duration of hospital stay over
time. Hence, incidence density (ie, incidence rate; number of
events per number of patient-days) will quantify the problem
of antimicrobial resistance more accurately than crude
numbers of events [4].
We quantiﬁed temporal trends in the microbiologic etiology
of nosocomial BSIs due to ARB and ASB in 14 hospitals in
Europe, North America, and South America over a 10-year
period. We categorized hospitals as those with and without
endemic ARB. We aimed to determine if ARB replace ASB, or




Institutional review boards in most of the participating hos-
pitals did not require a formal protocol review because
this study was retrospective and thus did not affect patient
care, and data were de-identiﬁed. Oxford data came from the
Infection in Oxfordshire Research Database, approved by the
Oxford Research Ethics Committee (09/H0606/85) and the
United Kingdom National Information Governance Board
(5–07(a)/2009).
Study Design, Study Setting, and Study Population
We performed a cohort study of patients with microbiologically
conﬁrmed nosocomial BSI by linking de-identiﬁed databases
from the hospital information systems and the microbiology
laboratories of the participating hospitals. Hospitals were eligi-
ble if they could provide (1) data on positive blood cultures,
including susceptibility proﬁles, for at least 7 consecutive
years, (2) numbers of hospital admissions and lengths of stay
for the same period, and (3) the hospital day during which
blood cultures were obtained. Patients admitted to ambulatory
care and psychiatric units were excluded. Species identiﬁcation
and susceptibility testing were performed according to local
guidelines and procedures.
We initially used the 2005 ﬁgures of methicillin-resistant
Staphylococcus aureus (MRSA) reported by existing surveil-
lance programs to categorize hospitals based on their countries’
proportion of MRSA among S. aureus invasive infections,
being more or less than 0.10, as having high or low infection
rates of ARB [5–7]. After data collection we quantiﬁed the
proportion of MRSA and ARB isolates and the incidence den-
sities of nosocomial MRSA BSI and ARB BSI in 2005.
Data Collection and Variables of Interest
The hospitals’ microbiological databases were linked to
patient-administrative systems, thereby providing a database
with all patient admissions. The database included microbio-
logical results of all positive blood cultures obtained, and data
on sex, age, department of admission, and length of stay
before nosocomial BSI acquisition. Hospital departments were
categorized as surgery, medicine, and mixed departments, and
patient care units were categorized as intensive care units or
regular wards.
Deﬁnitions
• Bloodstream infection: Isolation of bacteria or fungi from at
least 1 blood culture set. Microorganisms typically belonging
to the skin ﬂora (coagulase-negative staphylococci, Micrococcus
species,Bacillus species, ordiphtheroids [corynebacteria orprop-
ionibacteria]) were considered to be probable contaminants
and were excluded.
• Nosocomial BSI: BSIs occurring >48 hours after hospital
admission and in patients who did not have documented BSI
with the same microorganism during the ﬁrst 48 hours after
admission.
• Polymicrobial BSI: BSI with >1 microorganism in a single
set of blood cultures or in different blood culture sets obtained
within 48 hours of the ﬁrst positive blood culture.
• New episode of BSI: BSI caused by a different microorgan-
ism >48 hours after the previous nosocomial BSI or by the
same microorganism >30 days after the previous BSI.
• Antibiotic-resistant bacteria: Deﬁnitions of ARB were
based on a Dutch guideline (resistance criteria for isolation of
patients; Supplementary Table 1) [8]; these bacteria were sub-
divided in MRSA and non-MRSA ARB.
• Antibiotic-susceptible bacteria: Bacteria that did not meet
the deﬁnition of ARB according to the Dutch guideline.
Statistical Analysis
Data were analyzed from each hospital independently, and
from aggregate data from 2 groups, ARB-endemic and ARB-
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nonendemic hospitals. Although the participating hospitals
submitted data from somewhat different time periods, we as-
sessed trends in the rates of nosocomial BSI by pooling results
from the 10-year period 1998 to 2007. We did a sensitivity
analysis by repeating calculations from the period 2000 to
2005, for which all participating hospitals submitted data
(Supplementary Figure 1). In a second sensitivity analysis, we
excluded hospitals with the most extreme nosocomial BSI in-
cidence densities (Porto Alegre and Utrecht for the ARB-
endemic and ARB-nonendemic hospitals, respectively).
We assessed changes in the incidence densities of nosoco-
mial BSI to describe changes in the overall burden of disease
over time, and we assessed changes in the incidence densities
of cultured microorganisms (including each microorganism in
polymicrobial nosocomial BSI) to describe changes in burden
of nosocomial BSI infections caused by MRSA, ARB, and
ASB. Incidence densities were calculated as the number of
events per 100 000 patient-days. We modeled temporal trends
of incidence densities using Poisson regression, presenting
yearly change in incidence density as a rate ratio (RR) with a
95% conﬁdence interval (CI). To determine whether differenc-
es between RRs from ARB-endemic and ARB-nonendemic
hospitals were statistically signiﬁcant, we calculated the P
value for heterogeneity.
We repeated calculations with number of events per 10 000
admissions (cumulative incidence), to allow for the possibility
of nonparametric changes in length of stay after the onset of
nosocomial BSI compared to overall length of stay over the
study period, leading to an overestimation of increased burden
of disease when expressed as incidence densities (Supplemen-
tary Table 2).
We used the χ2 test for dichotomous variables, univariable
logistic regression for categorical variables, and Mann-
Whitney U test for continuous, nonnormally distributed vari-
ables to analyze relations between patients and ARB endemici-
ty. The data were analyzed using SPSS version 15.0 (SPSS,
Chicago, Illinois) and R version 2.6.0.
RESULTS
Hospital Characteristics
Fourteen hospitals from 9 countries participated: 7 hospitals
in countries with low proportions of MRSA among S. aureus
BSIs in 2005 [5] (the Netherlands [2 university hospitals, 2
general hospitals], Norway [1 university hospital], and Sweden
[1 university hospital, 1 general hospital]), and 7 in countries
with high proportions of MRSA among S. aureus BSI in
2005 [5–7] (Germany [2 university hospitals], Switzerland
[1 university hospital], United Kingdom [1 university hospi-
tal], Republic of Ireland [1 university hospital], United States
[1 university hospital], and Brazil [1 university hospital]). The
observed proportions of MRSA among S. aureus nosocomial
BSIs in 2005 ranged from 0.00 to 0.05 among hospitals in
countries with low prevalence of MRSA, and from 0.22 to 0.66
among hospitals in countries with high prevalence of MRSA.
The observed incidence densities of nosocomial MRSA BSI in
2005 ranged from 0.0 to 1.1 per 100 000 patient-days among
hospitals in countries with low MRSA rates and from 4.2 to
58 per 100 000 patient-days among hospitals in countries with
high MRSA rates. The observed incidence densities of nosoco-
mial ARB BSIs in 2005 ranged from 1.3 to 4.8 per 100 000
patient-days among hospitals in countries with low MRSA
rates (ARB-nonendemic hospitals) and from 9.9 to 91 per
100 000 patient-days among hospitals in countries with high
MRSA rates (ARB-endemic hospitals), which implies that the
proportion of MRSA—in these hospitals—is a reliable proxy
for ARB BSIs.
During the study period, 4 992 357 patients were admitted
for a total of 36.391 175 patient-days. The annual number of
patient-days increased by 0.3% among ARB-nonendemic hos-
pitals and 0.5% among ARB-endemic hospitals (Supplementary
Table 3).
Microbiology
Over the study period, 202 523 positive blood cultures were ob-
tained (not including probable contaminants) during 64 417
BSI episodes (Figure 1), of which 33 130 (51.4%) were hospital-
acquired, yielding 36 679 microorganisms: 9655 (25.9%) grew
Enterobacteriaceae, 7367 (22.6%) S. aureus, 3673 (11.4%) En-
terococcus species, 2824 (8.0%) Streptococcus species, 508 (1.5%)
other gram-positive species, 1670 (5.3%) Pseudomonas aerugi-
nosa, 640 (2.0%) Acinetobacter species, 1006 (3.3%) other
gram-negative species, 1666 (4.9%) fungi, 1104 (3.3%) anaer-
obes, and 3017 (8.3%) polymicrobial episodes. Of the nosoco-
mial BSIs, 30 178 (91.1%) were a patient’s ﬁrst nosocomial BSI
following hospital admission, and the remaining 2962 were pa-
tients’ second to ﬁfth episodes during the same hospital stay.
Nearly 14% (4484/33 130; 13.5%) of nosocomial BSIs were
caused by ARB: 18.8% (4040/21 452) in ARB-endemic hospitals
compared with 3.8% (444/11 688) in ARB-nonendemic hospi-
tals (P < .001). Nineteen percent (574/3017) of polymicrobial
nosocomial BSIs included at least 1 ARB.
Of nosocomial BSIs, 29 879 (90.1%) occurred between 1998
and 2007 (Table 1). Thus, data from this period were analyzed
to assess differences in trends between ARB-endemic and
ARB-nonendemic hospitals. The sensitivity analysis included
20 272 (61.2%) nosocomial BSIs that occurred from 2000
through 2005 (Supplementary Figure 1).
Patient Characteristics
Patients with nosocomial BSI had a median age of 61 years
(interquartile range [IQR], 42–73), 59.1% were male, and
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patients were hospitalized for a median of 13 days (IQR,
7–27) when their ﬁrst positive blood culture was obtained.
Thirty-six percent of nosocomial BSIs were acquired in a sur-
gical ward, 49.3% in a medical ward, and 14.4% in a mixed
surgical and medical ward. Twenty percent of nosocomial
BSIs were acquired in an intensive care unit. Compared with
bacteremic patients hospitalized in ARB-nonendemic hospi-
tals, patients in ARB-endemic hospitals were younger (59
years [IQR, 40–72 years] vs 63 years [IQR, 47–74 years]), had
longer lengths of stay before BSI acquisition (14 days [IQR, 7–
28 days] vs 13 days [IQR, 7–25 days]), were more likely to be
admitted to a medical ward (51.5% vs 45.0%), and were less
likely to be admitted to an intensive care unit (18.1% vs
24.1%; all comparisons P < .001).
Incidence Rates of Nosocomial BSIs
Between 1998 and 2007, the average incidence density of nos-
ocomial BSIs per hospital ranged from 62.3 to 185.5 per
100 000 patient-days. The 10-year trend of annual incidence
densities increased in 12 hospitals, decreased by 1% in 1 hos-
pital, and did not change signiﬁcantly in another one. The in-
crease in incidence densities was mainly due to increased rates
of Enterococcus species, anaerobes, and Candida species in
ARB-nonendemic hospitals and to Enterococcus species,
Enterobacteriaceae, Acinetobacter species, and Candida species
in ARB-endemic hospitals (Table 1). The incidence density
trends for nosocomial BSI caused by ASB, MRSA, and non-
MRSA ARB in the participating hospitals are shown in
Figure 2.
From 1998 to 2007, the incidence density of nosocomial
BSI caused by MRSA increased from 0.2 to 0.7 per 100 000
patient-days in ARB-nonendemic hospitals, an annual in-
crease of 22% (95% CI, 6%–40%). During the same period,
the incidence density of MRSA increased from 3.1 to 11.7 per
100 000 patient-days in ARB-endemic hospitals, correspond-
ing to an annual increase of 10% (95% CI, 9%–12%; Table 2).
Although the relative rates of increase did not differ signiﬁ-
cantly between ARB-nonendemic and ARB-endemic hospitals
(P = .2), the MRSA incidence density difference increased
from 2.9 in 1998 to 11.0 per 100 000 patient-days in 2007. The
incidence density of nosocomial BSIs caused by non-MRSA
ARB increased from 2.8 to 4.1 per 100 000 patient-days in
ARB-nonendemic hospitals, corresponding to an annual in-
crease of 5% (95% CI, 1%–9%). In the same period, the inci-
dence density of nosocomial BSIs caused by non-MRSA ARB
increased from 1.5 to 17.4 per 100 000 patient-days in ARB-
endemic hospitals, an annual increase of 22% (95% CI, 20%–
25%; P < .001; Table 2; Supplementary Figure 2). As a result,
Figure 1. Flow diagram of the study. Abbreviations: ARB, antibiotic-resistant bacteria; BSI, bloodstream infection.
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the incidence density difference between ARB-endemic and
ARB-nonendemic hospitals for nosocomial BSIs caused by
non-MRSA ARB increased from −1.3 per 100 000 patient-
days in 1998 to 13.3 per 100 000 patient-days in 2007.
Trends in incidence densities of nosocomial ASB BSIs were
similar, with annual increases of 4.5% (95% CI, 4%–5%) and
4.2% (95% CI, 4%–5%) in ARB-nonendemic and ARB-
endemic hospitals, respectively (P = .7). The overall incidence
density difference between ARB-endemic and ARB-nonen-
demic hospitals increased from 3.8 per 100 000 patient days in
1998 (78.1 vs 74.3 per 100 000 patient-days, respectively) to
24.4 per 100 000 patient-days in 2007 (130.1 vs 105.7 per
100 000 patient-days, respectively), fully attributable to infec-
tions caused by ARB (P < .001).
Sensitivity analyses evaluating data from 2000 to 2005 and
evaluating data that excluded data from the hospitals with the
highest rates yielded similar results (data not shown). More-
over, trends in cumulative incidences were comparable to
trends in incidence densities (Supplementary Table 2).
DISCUSSION
On the basis of detailed longitudinal data from 14 hospitals in
3 continent, we have demonstrated that an increasing inci-
dence of nosocomial BSIs caused by ARB adds to the total
burden of disease without replacing BSIs caused by more sus-
ceptible bacteria. While the total burden of nosocomial BSIs
in both cohorts was similar in 1998, the excess increase in
incidence rates of nosocomial BSIs in ARB-endemic hospitals
was 20.6 per 100 000 patient days in 2007 and almost fully
attributable to increased rates of infections caused by ARB.
To the best of our knowledge, this study is the ﬁrst to
conduct integrated trend analyses of all relevant nosocomial
pathogens on such a large multicenter dataset. This
dataset allowed us to quantify the overall burden of nosocomi-
al BSIs caused by ARB and ASB. Although longitudinal
changes in incidences and proportions of pathogens causing
nosocomial infections have been reported previously, in most
studies reported changes in the burden of disease due to ARB
reﬂected the epidemiology of a single pathogen [2, 9]. By com-
paring longitudinal data from hospitals with high and lower
rates of nosocomial ARB BSIs, we took advantage of a natural
experiment that allowed us to observe long-term effects of suc-
cessful and less successful control of nosocomial spread of
ARB. On a global level, this information is critical for assessing
beneﬁts of infection prevention and control strategies. In the
past years, guidelines have focused speciﬁcally on prevention
of ARB transmission in hospitals, in particular MRSA [10–13].
Our results stress the importance of successful prevention of
all ARB.
Although our study was observational, we feel that the
more pronounced increase of BSIs in the ARB-endemic hospi-
tals reﬂects either differences in infection prevention practices
or antibiotic prescription patterns, or both, of the hospitals
and their home countries [14, 15]. Our ﬁndings suggest that
hospitals (and their home countries) that effectively prevented
Table 1. Nosocomial Bloodstream Infections Caused by Speciﬁc Microorganisms During the Study Period (1998–2007) by Antibiotic-
Resistant Bacteria (ARB)–Nonendemic and ARB-Endemic Hospitals
Microorganism
ARB-Nonendemic Hospitals ARB-Endemic Hospitals
Heterogeneitya
Total ID Trend (ID) RR (95% CI) Total ID Trend (ID) RR (95% CI) P Value
Staphylococcus aureus 2216 16.2 1.01 (.99–1.03) 5113 27.0 1.05 (1.04–1.06) <.001
Enterococcus spp 1352 9.9 1.07 (1.05–1.09) 3037 16.0 1.06 (1.05–1.08) .9
Streptococcus spp 1100 8.0 1.02 (1.00–1.04) 1417 7.5 1.01 (.99–1.03) .4
Other gram-positives 198 1.4 1.08 (1.02–1.14) 281 1.5 1.15 (1.10–1.21) .06
Enterobacteriaceae 4205 30.7 1.05 (1.04–1.06) 6036 31.9 1.07 (1.06–1.08) .005
Acinetobacter spp 135 1.0 0.94 (.88–1.00) 626 3.3 1.10 (1.07–1.14) <.001
Pseudomonas aeruginosa 643 4.7 1.05 (1.02–1.08) 1229 6.5 1.05 (1.02–1.07) .9
Other gram-negatives 280 2.0 1.02 (.99–1.08) 646 3.4 1.05 (1.02–1.07) .6
Anaerobes 413 3.0 1.06 (1.02–1.10) 573 3.0 0.99 (.96–1.03) .008
Candida spp 522 3.8 1.06 (1.03–1.10) 1002 5.3 1.08 (1.05–1.10) .5
Polymicrobial 997 7.3 1.05 (1.03–1.08) 1680 8.9 1.04 (1.03–1.06) .6
Trend (ID) is secular changes in incidence density (on average, per year) of nosocomial bloodstream infections (number of infections per 100 000 patient-days)
from 1998 to 2007, stratified by pathogen.
Abbreviations: ARB, antibiotic-resistant bacteria; CI, confidence interval; ID, incidence density; RR, rate ratio.
a The statistical significance of the difference between RRs from ARB-endemic and ARB-nonendemic hospitals was assessed by calculating the P value for the
interaction term (calendar year–hospital type). P values <.05 indicate that the trends for ARB-endemic and nonendemic hospitals are significantly different.
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emergence of MRSA were also more successful in controlling
the more recent emergence of resistance among gram-negative
bacteria.
Three alternative explanations of our ﬁndings need to be ad-
dressed. The ﬁrst is an imbalanced change in patient case mix
that may have occurred during the study period. Such a change
in case mix was not discernible from observed changes in age
and length of stay. Moreover, annual changes in incidence rates
of ASB BSIs were similar in both hospital groups. The second
alternative explanation would be that ARB may be more viru-
lent than their susceptible counterparts, but this would contra-
dict the widely accepted view that resistance is associated with
reduced ﬁtness, and published studies do not convincingly
prove that antimicrobial resistance confers increased virulence
on pathogenic bacteria [16]. Finally, nonparametric changes in
length of stay after nosocomial BSIs compared with overall
length of stay could have caused us to overestimate the burden
of disease when expressed as incidence density. However, the
cumulative incidence, which is less sensitive to changes in the
number of patient-days over time, revealed similar trends.
Our study has several potential limitations. Hospitals were
included if they had the availability of an appropriate database,
which could have selected hospitals with better surveillance
systems and infection control policies. Naturally, results of the
various participating hospitals were heterogeneous, which
reﬂects differences in patient populations, local infection
prevention measures, hospital organization, and antibiotic pre-
scribing practices. Nevertheless, Figure 2 demonstrates broadly
similar results across our set of hospitals, and does not suggest
important ecological biases.
In addition, incidence density analysis in general might be
obscured when potential competing events (eg, in-hospital
death and hospital discharge) are not taken into account [17].
However, the incidence density of nosocomial BSIs, as deter-
mined in our study, was conditional on patients being alive
and hospitalized. Thus, the analysis of incidence densities cor-
responds to an analysis of the hazard for nosocomial BSIs
before in-hospital death or hospital discharge.
In theory, hospitals that obtained more blood cultures than
others might have higher rates of nosocomial BSIs. Because
information on negative blood cultures was not part of this
study, changes in blood culture practices over time could not
be determined. However, we are unaware of such changes in
the participating hospitals. Moreover, we think it is unlikely
that such changes differed between hospitals with high and
lower rates of nosocomial ARB BSIs.
Misclassiﬁcation may have occurred for some positive blood
cultures in patients who were discharged and then readmitted
soon thereafter with a BSI, erroneously classiﬁed as communi-
ty-acquired. Furthermore, we may have misclassiﬁed some nos-
ocomial BSIs as noninfectious by excluding cultures that grew
possible skin contaminants. Although some might have repre-
sented true episodes of nosocomial infection, we were unable to
identify them, as information of clinical signs and symptoms
was lacking [18]. However, misclassiﬁcation would have affected
rates of nosocomial BSI in a nondifferential manner.
Figure 2. Trends in incidence densities of microorganisms. Lines show trends in incidence densities over the study period for each hospital (antibiotic-
resistant bacteria [ARB]–endemic vs ARB-nonendemic hospitals) contributing data to the analysis. Light gray dashed line = ARB-endemic hospitals; dark
gray solid line = ARB-nonendemic hospitals. Different y-axis scales are used in each panel. A, Incidence densities of bloodstream infection (BSI) caused
by antibiotic-susceptible bacteria. B, Incidence densities of BSI caused by methicillin-resistant Staphylococcus aureus (MRSA). C, Incidence densities of
BSI caused by non-MRSA ARB. Abbreviations: ARB, antibiotic-resistant bacteria; ASB, antibiotic-susceptible bacteria; MRSA, methicillin-resistant Staph-
ylococcus aureus.
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In conclusion, we demonstrated that nosocomial BSIs caused
by ARB do not replace infections caused by more susceptible
bacteria, but rather these infections increase the total burden of
disease. This implies that successful control of antibiotic
resistance improves patient outcome not only because of lower
mortality from better treatable infections, but also because of a
reduction, or at least a lower increase, in number of infections.
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ARB-Nonendemic Hospitals ID
(Microorganisms per 100 000 Patient-Days)
ARB-Endemic Hospitals ID (Microorganisms














74.3 105.7 31.4 1.04 (1.03–1.04) 78.1 130.1 52.0 1.05 (1.05–1.06) <.001
ARB 3.0 4.7 1.7 1.06 (1.02–1.10) 4.6 29.1 24.5 1.15 (1.13–1.16) <.001
ASB 71.4 101.0 29.6 1.04 (1.03–1.04) 73.5 101.0 27.5 1.04 (1.03–1.04) .7
Staphylococcus aureus 15.7 16.3 0.6 1.01 (.99–1.03) 14.9 26.6 11.7 1.05 (1.04–1.06) <.001
MRSA 0.2 0.7 0.5 1.22 (1.06–1.40) 3.1 11.7 8.6 1.10 (1.09–1.12) .2
MSSA 15.6 15.6 0.06 1.01 (.99–1.02) 11.8 14.9 3.1 1.00 (.99–1.02) .8
Non– S. aureus
microorganisms
58.6 89.4 30.8 1.05 (1.04–1.05) 63.2 103.5 40.3 1.06 (1.05–1.06) .03
Non-MRSA ARB 2.8 4.1 1.3 1.05 (1.01–1.09) 1.5 17.4 15.9 1.22 (1.20–1.25) <.001
Enterococcus spp 0.0 0.1 0.1 1.33 (1.02–1.84) 0.6 3.1 2.5 1.22 (1.17–1.27) .6
Enterobacteriaceae 2.3 3.3 1.0 1.04 (1.00–1.09) 0.6 10.2 9.6 1.21 (1.18–1.25) <.001
Acinetobacter spp 0.3 0.1 −0.2 0.81 (.67–.96) 0.1 1.9 1.8 1.29 (1.20–1.39) <.001
P. aeruginosa 0.0 0.4 0.4 1.06 (.96–1.18) 0.1 1.3 1.2 1.19 (1.11–1.27) .08
Non-MSSA ASB 55.8 85.4 29.6 1.05 (1.04–1.05) 61.7 86.1 24.4 1.04 (1.04–1.05) .5
Enterococcus spp 8.4 14.2 5.8 1.07 (1.05–1.09) 8.8 11.5 2.7 1.05 (1.03–1.06) .09
Enterobacteriaceae 23.4 37.4 14.0 1.05 (1.04–1.06) 22.0 35.7 13.7 1.05 (1.04–1.06) .9
Acinetobacter spp 0.6 0.7 0.1 0.96 (.90–1.03) 1.3 4.0 2.7 1.07 (1.03–1.10) .007
P. aeruginosa 3.3 5.2 1.9 1.05 (1.02–1.08) 5.4 6.7 1.3 1.03 (1.01–1.05) .3
Trend is secular changes in incidence density (on average, per year) of nosocomial bloodstream infections (number of infections per 100 000 patient-days) from
1998 to 2007, stratified by pathogen.
Abbreviations: ARB, antibiotic-resistant bacteria; ASB, antibiotic-susceptible bacteria; CI, confidence interval; ID, incidence density; MRSA, methicillin-resistant
Staphylococcus aureus; MSSA, methicillin-susceptible Staphylococcus aureus; P. aeruginosa, Pseudomonas aeruginosa; RR, rate ratio.
a MRSA, MSSA, non-MRSA ARB, and non-MSSA ASB.
b The statistical significance between RRs from ARB-endemic and ARB-nonendemic hospitals was assessed by calculating the P value for the interaction term
(calendar year–hospital type). P values <.05 indicate that the trends for ARB endemic and nonendemic hospitals are significantly different.
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